V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220014137 | 220008637 | 1.65 | 73 | Palliative (P) | 2016-04-21 | 2016-04-29 | CYCLOPHOSPHAMIDE + FLUDARABINE | Y | Y | 220032608 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220014138 | 220008638 | 1.68 | null | Disease modification (D) | 2016-11-17 | 2016-11-17 | FLAG | 01 | N | 220032608 | FLAG |
| 220014139 | 220008639 | 1.61 | 86.8 | Curative (C) | 2015-08-08 | 2015-08-19 | AML Int Guide ADE 10+3+5 (1) | N | null | 220032610 | ADE |
| 220014140 | 220008642 | 0 | 74.2 | Curative (C) | null | 2017-03-31 | Methotrexate intrathecal | N | N | 220032610 | METHOTREXATE INTRATHECAL |
| 220014141 | 220008644 | null | 72 | Curative (C) | 2018-07-26 | 2018-08-06 | BOSUTINIB | N | N | 220032617 | BOSUTINIB |
| 220014142 | 220008645 | 0 | 71.8 | Adjuvant (A) | 2014-11-18 | 2015-01-02 | Triple Intrathecal | 2 | N | 220032618 | TRIPLE INTRATHECAL |
| 220014143 | 220014662 | null | null | Curative (C) | 2018-06-02 | 2018-06-03 | FLAG | 02 | null | 220032624 | FLAG |
| 220014144 | 220014662 | 1.8 | 56 | Curative (C) | null | 2017-04-12 | CYCLOPHOSPHAMIDE + FLUDARABINE | Y | N | 220032624 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220014145 | 220008647 | 1.78 | null | null | 2013-07-02 | 2013-07-03 | Idarubicin+Tretinoin Spanish Crse2 | N | N | 220032627 | IDARUBICIN + TRETINOIN |
| 220014146 | 220008648 | 1.7 | 95.7 | null | 2013-09-27 | 2013-10-01 | Triple Intrathecal | N | N | 220032628 | TRIPLE INTRATHECAL |
| 220014147 | 220014663 | 1.77 | null | Curative (C) | 2018-01-04 | 2018-01-07 | ATG + Busulfan + Fludarabine | N | null | 220032628 | ATG + BUSULFAN + FLUDARABINE |
| 220014148 | 220014663 | 1.85 | 66.2 | Curative (C) | 2015-07-13 | 2015-07-15 | Cyclophosphamide+Fludara+TBI Allo | 02 | N | 220032628 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220014149 | 220008649 | 1.82 | 68.8 | Curative (C) | 2014-03-05 | 2014-03-12 | Cyclophosphamide TBI Allograft | N | N | 220032635 | CYCLOPHOSPHAMIDE |
| 220014150 | 220008650 | null | 65.7 | Curative (C) | 2016-03-09 | 2016-03-09 | CYCLOPHOSPHAMIDE + FLUDARABINE | N | N | 220032637 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220014151 | 220008650 | 1.69 | 81.2 | Disease modification (D) | 2016-09-27 | 2016-09-28 | Triple / Double Intrathecal Therapy | Y | N | 220032637 | TRIPLE INTRATHECAL |
| 220014153 | 220008652 | 1.63 | null | Curative (C) | 2016-08-15 | 2016-08-20 | AML Int Guide ADE 8+3+5 (2) | N | N | 220032654 | ADE |
| 220014154 | 220008654 | 1.67 | null | Curative (C) | null | 2015-09-24 | AML Int Guide ADE 8+3+5 (2) | 2 | null | 220032654 | ADE |
| 220014155 | 220008656 | 1.75 | 71.5 | Curative (C) | 2014-12-30 | 2015-01-08 | CYCLOPHOSPHAMIDE + FLUDARABINE | N | N | 220032656 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220014156 | 220008658 | 1.62 | 9.2 | null | null | 2017-12-03 | IDARUBICIN + TRETINOIN | N | N | 220032658 | IDARUBICIN + TRETINOIN |
| 220014157 | 220008661 | 0 | 55.9 | Disease modification (D) | 2016-05-03 | 2016-05-03 | ATG + Busulfan + Fludarabine | 02 | N | 220032660 | ATG + BUSULFAN + FLUDARABINE |
| 220014158 | 220008661 | 1.9 | 75.4 | Curative (C) | 2017-03-18 | 2017-03-21 | IDARUBICIN + TRETINOIN | 02 | null | 220032660 | IDARUBICIN + TRETINOIN |
| 220014159 | 220008662 | null | 42.8 | Curative (C) | 2016-04-15 | 2016-04-16 | Idarubicin+Tretinoin Spanish Crse2 | 99 | N | 220032665 | IDARUBICIN + TRETINOIN |
| 220014161 | 220008666 | 1.75 | null | Palliative (P) | 2014-03-01 | 2014-03-01 | Triple Intrathecal | N | N | 220032681 | TRIPLE INTRATHECAL |
| 220014162 | 220008670 | 1.68 | null | Curative (C) | 2017-11-09 | 2017-11-16 | BOSUTINIB | N | N | 220032682 | BOSUTINIB |
| 220014163 | 220008671 | null | 39.7 | Curative (C) | null | 2016-03-05 | Idarubicin+Tretinoin Spanish Crse4 | N | N | 220032692 | IDARUBICIN + TRETINOIN |
| 220014164 | 220008673 | 1.85 | 88.6 | Curative (C) | 2013-04-26 | 2013-05-07 | Triple / Double Intrathecal Therapy | N | N | 220032694 | TRIPLE INTRATHECAL |
| 220014165 | 220008675 | 1.52 | null | Disease modification (D) | 2013-10-21 | 2013-10-21 | Methotrexate intrathecal | N | N | 220032695 | METHOTREXATE INTRATHECAL |
| 220014166 | 220008678 | 1.72 | 67.8 | Curative (C) | null | 2016-06-08 | AML16 DA 3+10 | 02 | N | 220032698 | AML16 TRIAL |
| 220014168 | 220008683 | null | null | Curative (C) | 2015-06-28 | 2015-06-28 | Triple / Double Intrathecal Therapy | N | N | 220032713 | TRIPLE INTRATHECAL |
| 220014169 | 220014675 | null | null | Curative (C) | 2013-05-20 | 2013-05-20 | FLAG | N | N | 220032716 | FLAG |
| 220014170 | 220008685 | 0 | 51.9 | Palliative (P) | 2016-12-12 | 2016-12-23 | FLAG | 2 | N | 220032717 | FLAG |
| 220014171 | 220008685 | 1.66 | 0 | Disease modification (D) | 2013-09-12 | 2013-09-18 | AML Int Guide ADE 10+3+5 (1) | 2 | N | 220032717 | ADE |
| 220014172 | 220008687 | 1.73 | 17.5 | Curative (C) | 2013-12-30 | 2014-03-15 | BOSUTINIB | 2 | N | 220032722 | BOSUTINIB |
| 220014173 | 220008688 | 1.25 | 21.5 | Disease modification (D) | 2017-03-02 | 2017-03-17 | BOSUTINIB | N | N | 220032724 | BOSUTINIB |
| 220014174 | 220008689 | 1.66 | 50.4 | Curative (C) | 2017-02-07 | 2017-02-07 | Cyclophosphamide+Fludara+TBI Allo | Y | N | 220032724 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220014175 | 220008690 | null | 81 | Curative (C) | null | 2013-06-04 | Cyclophosphamide TBI Allograft | N | N | 220032727 | CYCLOPHOSPHAMIDE |
| 220014176 | 220008692 | 1.68 | 103.5 | Curative (C) | 2017-12-08 | 2017-12-17 | Triple / Double Intrathecal Therapy | N | N | 220032728 | TRIPLE INTRATHECAL |
| 220014177 | 220014679 | 1.56 | 68 | null | 2016-07-28 | 2016-07-28 | RUXOLITINIB | N | N | 220032730 | RUXOLITINIB |
| 220014178 | 220008698 | null | 28.85 | Curative (C) | 2017-04-10 | 2017-04-11 | BOSUTINIB | 2 | N | 220032735 | BOSUTINIB |
| 220014179 | 220008699 | 1.67 | null | Curative (C) | 2017-02-23 | 2017-02-23 | Methotrexate intrathecal | Y | N | 220032740 | METHOTREXATE INTRATHECAL |
| 220014180 | 220008700 | 1.65 | 49.8 | Disease modification (D) | 2017-03-06 | 2017-04-11 | Idarubicin+Tretinoin Spanish Crse2 | N | N | 220032742 | IDARUBICIN + TRETINOIN |
| 220014181 | 220008701 | 1.91 | 10.2 | Curative (C) | null | 2017-10-27 | AML16 DA 3+8 | N | N | 220032750 | AML16 TRIAL |
| 220014182 | 220008701 | null | 81.5 | Curative (C) | 2014-01-28 | 2014-03-07 | AML Int Guide ADE 10+3+5 (1) | N | N | 220032750 | ADE |
| 220014183 | 220008701 | null | 57.6 | null | 2014-01-25 | 2014-01-25 | CYCLOPHOSPHAMIDE | Y | null | 220032750 | CYCLOPHOSPHAMIDE |
| 220014184 | 220008702 | 1.65 | 80 | Curative (C) | 2014-12-26 | 2014-12-29 | BOSUTINIB | N | N | 220032770 | BOSUTINIB |
| 220014185 | 220014683 | 1.96 | null | null | 2017-01-12 | 2017-01-13 | Cyclophosphamide TBI Allograft | null | N | 220032771 | CYCLOPHOSPHAMIDE |
| 220014186 | 220014683 | null | 107.5 | Curative (C) | 2015-10-24 | 2015-12-02 | BOSUTINIB | 02 | Y | 220032771 | BOSUTINIB |
| 220014187 | 220014683 | 1.55 | 75 | Curative (C) | 2014-11-14 | 2014-11-20 | AML16 DA 3+8 | N | N | 220032771 | AML16 TRIAL |
| 220014188 | 220008709 | 1.72 | 95.3 | Curative (C) | null | 2017-03-22 | CYCLOPHOSPHAMIDE + FLUDARABINE | 2 | N | 220032780 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220014189 | 220008710 | null | 81 | Curative (C) | 2014-12-18 | 2014-12-22 | CYCLOPHOSPHAMIDE + FLUDARABINE | null | null | 220032781 | CYCLOPHOSPHAMIDE + FLUDARABINE |